Access Pharmaceuticals has announced plans to begin additional human trials of its novel platinum polymer drug.

The company has revealed that it will launch the new phase of trials in late 2007 or early 2008 as part of the ongoing clinical trial of its ProLindac platinum-based drug.

The drug is designed to treat recurrent ovarian cancer patients.

Commenting on the progress of the drug, Access' European Vice Chairman, Dr Esteban Cvitkovic, said: "The excellent safety profile, especially the lack of neuro- and nephro-toxicity after multiple treatment cycles, makes it possible for us now to submit an amendment to the ongoing trial which will allow us to further and aggressively explore dosing and schedule optimization in a quicker manner."

Meanwhile, Stephen R Seiler, Chief Executive of Access, added: "As a result of the ProLindac results to date, we have put plans in place for ProLindac manufacturing scale-up in advance of starting these additional clinical trials and enrolling additional patients."

Source:

Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac, 20/08/07
http://money.cnn.com/news/newsfeeds/articles/prnewswire/LAM01420082007-1.htm

Ÿ Adfero Ltd